MSTN and myocardial infarction: In support of this observation, others have recently demonstrated that the myostatin/ACVR2B signalling is up‐regulated in the heart of patients with heart failure75 and that targeting ACVR2B can improve cardiac function in models of ageing, ischaemia, and myocardial infarction, thereby implicating activin signalling as a negative input on cardiac function.76, 77, 78